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Genetic Alterations in Carcinogenesis and
Chemoprevention
by Miriam P. Rosin
Laboratory and clinical studies suggest that genetic change is intrinsically involved in the development of
cancer and that this change occurs in humans throughout carcinogenesis, in both early and late stages.
Therefore, thequantification ofthe levelofgenetic change in human epithelial tissues mayserve as amarker
for cancer risk. The micronucleus test has been used to quantify the level of site-specific chromosomal
breakage occurring in epithelial tissues of individuals at elevated risk for cancer. These studies include
individualsexposedtocarcinogens, patients whohavechromosome-breakage syndromes, andindividualswith
premalignant lesions. As a counterpart to this approach, the assay has been used to study the suppression of
this breakage with chemopreventive agents, some ofwhich occur naturally in the diet. These agents include
P-carotene, retinyl palmitate, 13-cis-retinoic acid, riboflavin, canthaxanthin, and folic acid. Not all ofthese
agents were effective. The success ofthe treatmentdepended on both the agentbeingused andthe population
being studied. The results ofthese studies suggest that successful intervention with chemopreventive agents
will depend ontailoringtreatment regimens to specific populations. The micronucleus test can be used along
with other biological end points to obtain an early indication of the efficacy of chemopreventive agents in
altering biological changes associated with carcinogenesis in tissues ofhigh-risk individuals.
Introduction
In 1982, a National Academy of Science committee
examined the epidemiological and laboratory evidence for
the role ofdiet in cancer development (1). This committee
issued areport that drewthe attention ofboth the general
publicand scientists to anassociationbetween dietsrichin
specific compounds and a lower risk of cancer. Interven-
tiontoprevent cancerdevelopmentinhigh-riskindividuals
became an intriguing possibility. Many scientists began
focusing their research on identifying agents with the
potential to inhibit cancer development (collectively
termed chemopreventive agents) and, ultimately, on devel-
oping approaches for evaluating their effectiveness in
reducing cancer incidence in humans.
After adecadeofresearch, scientists areonlybeginning
to understand how and when chemopreventive agents can
be used to protect humans from cancer. However, the
feasibility of this approach has been demonstrated in
several clinicaltrials, themajorityofwhich have examined
the efficacy of chemopreventive agents in reversing pre-
malignant lesions. To date, only two trials have been
completed in which cancer itself has been shown to be
reduced by chemoprevention in a high-risk population. In
bothtrials,populations were choseninwhich cancerdevel-
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opmentwas expected to occur at ahigh ratewithin avery
short time span. Hong and co-workers (2,3) studied
patients that had been successfully treated for head and
neck squamous cell carcinomas, a group ofindividuals in
whichsecondaerodigestivemalignanciesoccuratarateof
3-5% per year (2,3). Treatment with 13-cis-retinoic acid
(cRA) for 12 months resulted in a significant decrease in
the incidence ofsecond primary tumors. After 42 months
of follow-up, only 6% of cRA-treated patients developed
tumors, compared with 27% of patients receiving a
placebo. Kraemer and co-workers (4) studied the efficacy
of cRA in suppressing the development of carcinomas in
xeroderma pigmentosum patients. These patients had a
history ofmultiple cutaneous carcinomas, on average 12.1
tumors per year before treatment. During a2-year treat-
mentperiodwithcRA, tumorformationwasreducedtoan
average of2.5peryear. However,when the treatmentwas
discontinued, the tumor frequency increased.
Both of these studies focus attention on an issue of
majorconcernincurrenteffortstodesigneffectivechemo-
prevention trials. The dataindicate thatlong-term admin-
istrationofanagentisrequiredforsuccessfulintervention
because lesions relapse when treatment with the chem-
opreventive agentis discontinued. Chronic administration
ofcRAis limitedbypotential toxicityand sideeffects. The
choice of which agent or combination of agents to use in
future regimens is formidable because over a thousand
possible chemopreventive agents have been identified. To
address this problem, many ofthe ongoing clinical trials
are using batteries of"intermediate markers" to identifyM. P ROSIN
biological changes that can be used as quick screens for
thepotential efficacyofchemopreventive agentsin specific
human populations. Such biological markers could be used
to design chemoprevention studies onindividuals atearlier
stages of carcinogenesis, before the development of any
clinical lesion. This paper describes this approach ofusing
intermediate end points as surrogates for clinical lesions
and for cancer itself. More specifically, this paper summa-
rizes recent studies on one such biological marker, the
micronucleus test on epithelial cells.
Biological Markers for Intervention
Certain biological events are viewed as intrinsically
involvedinthedevelopmentofcancer. Theseeventsinclude
the progressive accumulation of alterations to specific
genes and a dysregulation of cell proliferation and differ-
entiation controls. Cells no longer mature and senesce, but
become immortal. As part of this process of change,
promotingagents havebeen shown to stimulate inflamma-
tory reactions and to elevate rates of cell division.
Thelastdecade has seenthe development ofavarietyof
biological assays focused on quantifying these critical
eventsincarcinogenesis (Table1). Each oftheseassaysis a
potential intermediate marker that can be used to screen
forchemopreventive agents. Manyofthesemarkershave a
long history ofdevelopment in laboratory studies and are
only now being modified for human studies. For example,
micronucleiarenowbeingevaluated inepithelialtissuesby
collecting cells as they are exfoliated from the tissue. In
many cases, such samples can be obtained noninvasively
such as by swabbing the buccal mucosa with a moistened
tongue depressor to examine the oral cavity or by cen-
trifuging urine to collect cells from the urogenital tract.
Other assays are being modified to be performed on
biological fluids such as urine, blood, or saliva or on fine-
needle aspirates. In addition, a large effort is being made
to increase the information that can be generated from
tiny-punch biopsies. Hence, microtechniques are evolving,
such as the use ofin situ hybridization with chromosome-
specificprobes toquantifyaneuploidyintissues, theuse of
polymerase chain reactions to identify specific DNA
Event
Genetic change
lable 1. Chemoprevention by event.
Potential in vivo biological markers
Micronuclei, aneuploidy (via in situ hybridization with chromosome-
specific probes), chromosomal aberrations (via premature chromosome
condensation), DNA adducts
Proliferation Ornithine decarboxylase activity, antigens for specific proteins (Ki67,
PCNA), transcription ofgenes involved in proliferation (c-myc, PCNA),
and identification ofS-phase cells by tritiated thymidine labeling,
incorporation ofbromodeoxyuridine or flow cytometry
Inflammation Indicators of oxidative stress (oxidized DNA bases including thymidine
glycol and 8-hydroxyl-2-deoxy-guanosine), induction of proto-oncogenes
(c-fos, c-jun)
Differentiation Immunohistochemical quantification of specific proteins (e.g., keratins)
Senescence Histological evidence ofapoptosis (programmed cell death)
Abbreviations: PCNA, proliferating cell nuclear antigen; DFMO, difluoromethylornithine.
alterations in cells, and the use of a range of monoclonal
antibodies to study minute alterations in both the quan-
tities and types ofprotein products in a tissue.
Aside from developing intermediate markers and fine-
tuning them for use in human populations, laboratory
scientists have another large role to play in the area of
chemoprevention. Over the years, laboratoryresearch has
generated a basic understanding of the diverse mecha-
nisms by which chemopreventive agents act to suppress
tumorigenesis (5) Scientists are beginning to classify
potential chemopreventive agents by their expected mode
of action. Thus, lists have been made of antioxidant scav-
engers, anti-inflammatory agents, inhibitors of cell pro-
liferation, hormone antagonists, inducers ofcell differenti-
ation, modifiers of oncogene expression, and so on. This
information canbeusedtomatchendpointsandagentsfor
use in clinical trials of specific populations.
Micronucleus Test on Epithelial Cells
Themicronucleus testis aprime candidate foruse as an
intermediate marker of chemoprevention because this
assaymeasures aneventhighlyrelevantto carcinogenesis.
Currentindications are that aprogressive accumulation of
genetic alterations is required for cancer to develop, with
these changes occurring throughout carcinogenesis. A
chronic increase in the level ofgenetic damage in a tissue
should be associated with an elevation in risk for cancer at
thatsite. Suppression ofthis damagewith achemopreven-
tive agent could be expected to reduce risk by decreasing
theprobabilityofthetissue accumulatingall ofthegenetic
changes required for cancer to develop. The use of the
micronucleus test as an index of cytogenetic damage is
well supported in the literature. Although the test has
been most widely used to study genetic damage in vivo in
preparations from bone marrow and peripheral blood, the
assayhas thepotential formeasuring damage at avariety
ofother sites includingthe oral mucosa, lung, liver, spleen,
urinarybladder, testis, cervix, vagina, esophagus, corneal
epithelium, skin, and hair follicles (6).
To date, themicronucleus testhasbeen used to quantify
chromosomal breakage in epithelial tissues in over 30
Examples of chemopreventive agents
Radical scavengers and antioxidants (d-carotene);
Inhibitors of carcinogen bioactivation (oltipraz)
Retinoids, calcium, wheat fiber, DFMO
Scavengers of reactive oxygen species (,B-
carotene, ascorbate, ax-tocopherol), anti-
inflammatory agents (ibuprofen, indomethacin)
13-cis-retinoic acid
13-cis-retinoic acid
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groups ofindividuals atrisk for cancer (7,8). These groups
include individuals with risk factors associated with life-
style (e.g., tobacco or alcohol usage, poor diets), genetics
(e.g., individuals belonging to cancer-prone syndromes
such asxerodermapigmentosum, ataxia-telangiectasia, or
Bloom syndrome), or potential occupational hazards (e.g.,
pesticides); patientswithpremalignantlesions (e.g.,leuko-
plakias, dysplasias, metaplasias); and more recently, indi-
viduals with pathological conditions associated with
chronic inflammation and irritation (e.g., schistosomiasis
patients). Together, these studies have included analyses
performed on preparations from the oral mucosa, the
urinary bladder, the esophagus, the bronchi, and the cer-
vix. In each case, a significant elevation occurred in micro-
nucleus frequencies in samples from the high-risk group
compared with those concurrently taken from controls.
More importantly, the elevation occurred in the tissue at
the site at risk for cancer.
Micronucleus Test in
Chemoprevention Studies
In1983, weproposed the use ofthemicronucleus test on
epithelial cells as a method of estimating the efficacy of
chemopreventionregimens (9). Thisproposal wasbased on
two observations. First, we had been studying the tem-
poral pattern of micronucleus production in cancer
patients receiving radiotherapy to the head and neck
region. An increase in micronucleated mucosal cells from
the irradiated area occurred within 1 week ofthe patient
commencing treatment. The micronucleus frequency
increased throughout treatment, then rapidly declined to
values observed in untreated tissues within 1 month of
cessation of treatment. This response was thought to
reflect the time for cells in the basal cell layer of the
epithelium to divide one to two times, followed by matura-
tion and migration to the surface (7). The second observa-
tion came from a study concurrently running in the
Philippines amongchewers ofbetel quid, amixture ofbetel
nut, betel leaf, tobacco, and lime. This chewing habit is
strongly associated with an increased risk for oral cancer.
An increased frequency of micronucleated cells was
observed in exfoliated cell samples obtained by swabbing
the oral mucosa ofthese chewers. It was reasoned thatif a
chemopreventive agent was to be effective in protecting
against genotoxic damage, the response should be quickly
apparent as areduction in micronucleus frequencies in the
carcinogen-exposed tissue of such individuals. An inter-
vention trial was initiated inwhich a group ofchewers was
given oral supplements ofvitamin A (50,000 units retinyl
palmitate) and 1-carotene (90 mg) twice weekly for 3
months. Although the participants continued chewing,
micronucleus frequencies began to decreasewithin 4weeks.
By 3 months, the average frequency ofmicronucleated cells
had decreased from4.6 to 0.96%. Frequencies in individuals
receiving placebo treatment remained unchanged.
Since this study waspublished, otherintervention trials
have used the micronucleus test as an intermediate
markerforchemoprevention (Table2). Thesetrials encom-
pass studies on the oral cavity, urinary bladder,
esophagus, and lung and involve several different agents,
although f-carotene andvitaminA(asretinylpalmitate or
as 13-cis-retinoic acid) have been most frequently used.
Although these studies are limited in number, they have
begun to provide insight into the specificity of action of
chemopreventive agents in blocking genetic damage in
different populations. For example, several different
agents and combinations ofagents havebeenusedintrials
on betel quid chewers. Trials in which 3-carotene, retinyl
palmitate, or a combination ofthese two agents were used
all resulted in a significant reduction in micronucleus
frequencies. However, when canthaxanthin or folic acid
was used, the frequencies remained unchanged. These
data suggest that intervention regimens will have to be
carefully chosen for specific populations. In further sup-
port ofthis observation are datafrom studieswith reverse
smokers in the Philippines. Reverse smokers hold the lit
end of the cigarette in their mouths, a habit associated
Table 2. Reduction ofgenetic damage in high-risk individuals by oral supplementation with chemopreventive agents. (7,8).
Population Tissue Treatment MN frequency Lesion
Betel quid chewers Oral cavity (buccal mucosa) f-carotene Decreased Partial remission
Retinyl palmitate Decreased Partial remission
,B-carotene, retinyl palmitate Decreased Partial remission
Canthaxanthin No effect No effect
Folic acid No effect No effect
Reverse smokers Oral cavity (palate) ,B-carotene, retinyl palmitate No effect No effect
Xeroderma pigmentosum Oral cavity (tongue) ,8-carotene Decreased NE
patients
Snuff-users Oral cavity (labial mucosa) 1-carotene Decreased NE
Schistosomiasis patients Urinary bladder Praziquantel Decreased NE
Individuals with Oral cavity 13-cis-retinoic acid Decreased Partial remission
premalignant lesions Oral cavity Riboflavin and retinyl and zinc No effect No effect
Esophagus Riboflavin and retinyl and zinc acid Decreased No effect
Lung 13-cis-retinoic acid In progress In progress
NE, end point was not examined.
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with an elevatedriskfor oral cancer. Although ,B-carotene/
retinyl palmitate supplementation was very effective in
protecting betel quid chewers against genetic damage in
the oral cavity, this combination had no effect on micro-
nucleus frequencies in reverse smokers.
Anissuethatneedstobeemphasizedwithrespecttothe
designoffutureinterventiontrialsusingmicronucleiisthe
crucial importance of obtaining as detailed a description
as possible ofthe population undergoing intervention. To
date, these groups have involved individuals from many
countries, with obvious differences in lifestyle habits, diet,
type of carcinogen exposure, socioeconomic status, and
many other parameters. In some cases, individuals were
chosen to participate in a trial on the basis of a known
carcinogen exposure, such as in the choice of betel quid
chewers, reverse smokers, and snuff users. In other
instances, individuals were chosen because they had pre-
malignant lesions. Whether differences in the stage of
carcinogenesis between individuals with and without
lesions will play a role in the success of intervention is
unknown. In trials inwhich micronucleus frequencies and
lesion response were concurrently monitored, the two end
points often showed a parallel response. A decrease in
micronucleus frequencies in a tissue was followed some-
what later by at least a partial remission ofthe premalig-
nant lesions [Table 2, (7)].
Two recently completed studies have focused on other
speciflc characteristics in the trial population. A study on
xeroderma pigmentosum patients was the first to show
that genetic damage was suppressed by chemoprevention
in individuals genetically predisposed to cancer (M. P.
Rosin and W. Anwar, unpublished data). This intervention
occurred in samples obtained from the dorsal tip of the
tongue, a site in these patients atwhich carcinomas occur
at a frequency 20,000 times greater than in controls. The
second study involved patients infected with the parasite
Schistosoma haematobium, an infection strongly associ-
atedwithcanceroftheurinarybladder(10). Severalrecent
reviews have suggested that tissue trauma and inflamma-
tory reactions may play an important role in cancer.
Schistosomiasis patients are ideal models for studies of
this relationship. Micronucleus frequencies were shown to
be significantly elevated in urothelial cells obtained from
infected individuals. These frequencies decreased tolevels
observed in noninfected controls after treatmentwith the
antischistosomal drug praziquantel. This study is impor-
tantbecause it suggests that genetic damage could be one
mechanismwherebychronicinfections couldincrease can-
cerrisk. Whether aradical scavenger, such as 3-carotene,
could protect the urothelium from genetic damage during
infection is unknown. Such a possibility requires consid-
eration because reinfection is a common problem in
schistosomiasis patients. A case could be made for using
chemoprevention with a nontoxic component such as
,-carotene between praziquantel treatments to protect
schistosomal patients from damage to the urothelium due
to reinfection.
Conclusions
Large-scale, long-term clinical trials are required to
determine whether responses of specific, intermediate
markers to chemoprevention will accurately reflect a
reduced incidence ofcancer in a supplemented population.
However, until such studies are completed, much can be
learned about the chemopreventive process by using bat-
teries of end points in studies of high-risk populations.
Such intermediate markers mayplay amajorrole not only
in defining trial populations in more detail, but also in
increasing ourunderstanding ofthe carcinogenic process.
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